Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment

AIMS: Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME). This study compared outcomes of patients with DME switched directly to an FAc implant, versus indirectly via dexamethasone, after anti-VEGF therapy fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehak, Matus, Busch, Catharina, Unterlauft, Jan-Darius, Jochmann, Claudia, Wiedemann, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093402/
https://www.ncbi.nlm.nih.gov/pubmed/31749051
http://dx.doi.org/10.1007/s00592-019-01439-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093402/
https://www.ncbi.nlm.nih.gov/pubmed/31749051
http://dx.doi.org/10.1007/s00592-019-01439-x

Ejemplares similares